64
Participants
Start Date
September 1, 2021
Primary Completion Date
October 25, 2022
Study Completion Date
October 25, 2022
KRN125(pegfilgrastim), PLR001(plerixafor)
7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
KRN8601(filgrastim), PLR001(plerixafor)
400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
Nagoya City University Hospital, Nagoya
The Jikei University Kashiwa Hospital, Kashiwa
Hospital of the University of Occupational and Environmental Health, Kitakyushu
Hokkaido University Hospital of the National University Corporation, Sapporo
Kobe City Medical Center General Hospital, Kobe
Ishikawa Prefectural Central Hospital, Kanazawa
Tokai University Hospital, Isehara
Kanagawa Cancer Center, Yokohama
Jichi Medical University Hospital, Shimotsuke
Juntendo University Hospital, Bunkyo-ku
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku
Japanese Red Cross Medical Center, Shibuya-ku
Chiba Cancer Center, Chiba
Kyushu University Hospital, Fukuoka
Kagoshima University Hospital, Kagoshima
Kochi Health Sciences Center, Kochi
National Hospital Organization Kumamoto Medical Center, Kumamoto
Niigata University Medical and Dental Hospital, Niigata
National Hospital Organization Okayama Medical Center, Okayama
Osaka International Cencer Institute, Osaka
Wakayama Medical University Hospital, Wakayama
Kyowa Kirin Co., Ltd.
INDUSTRY